News > Cipremi: Cipla launches 100 mg antiviral drug to treat severe Covid-19 patients

Cipremi: Cipla launches 100 mg antiviral drug to treat severe Covid-19 patients

Cipla, an Indian pharmaceutical company, has launched its own antiviral drug named Cipremi for treating severe COVID-19 patients. 'Cipremi' has been approved for adult and paediatric patients who have been hospitalised. The newly launched drug will be more effective for those who are on oxygen support after falling ill to coronavirus.

Cipremi will be available as Remdesivir lyophilised powder for 100mg injection through Government and open market channels. Pricing of the drug has still not been disclosed yet.